Skip to main content
Pharmaceutical Centre S.A. logo

Pharmaceutical Centre S.A. — Investor Relations & Filings

Ticker · VITAF ISIN · GRS821003001 LEI · 213800MM1BRNC3393O45 CSE Wholesale and retail trade
Open in API
Filings indexed 5 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country GR Greece
Listing CSE VITAF

About Pharmaceutical Centre S.A.

https://www.lelosgroup.gr/vitafarm

Pharmaceutical Centre S.A., operating under the trade name Vitafarm, is a pharmaceutical wholesale group. The company's core activity is the marketing and distribution of a wide range of products to a nationwide network of pharmacies. Its portfolio includes pharmaceuticals, parapharmaceuticals, health products, nutritional supplements, medicated products, and vitamins. The company also engages in representations and exclusive imports of certain products.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2026
Regulatory Filings
2026-05-08 Greek (modern)
AGM Information 2026
AGM Information
2026-04-29 Greek (modern)
Annual Report 2025
Annual Report Classification · 92% confidence The document is titled “Ετήσια Χρηματοοικονομική Έκθεση” for the 1 January to 31 December 2025 period, prepared under IFRS as adopted by the EU. It contains the full suite of annual report components: Board of Directors’ report, independent auditor’s report, consolidated and company financial statements (statement of financial position, income, cash flows, equity changes), extensive notes, risk disclosures, strategic overview and profit distribution proposals. The length (~176k characters) and detailed financial content confirm this is the complete annual report itself, not merely an announcement or summary. Therefore, it fits the “Annual Report” category (10-K). FY 2025
2026-04-29 Greek (modern)
Regulatory Filings 2026
Regulatory Filings Classification · 60% confidence The document is an announcement (ΑΝΑΚΟΙΝΩΣΗ) to the Cyprus Stock Exchange notifying the convocation of the Board of Directors meeting to approve the annual financial statements for fiscal year 2025. It is not the financial statements themselves nor the publication of the report but a regulatory notice regarding a corporate meeting. It does not announce any board member changes, dividends, delisting, or other specific transactions. Therefore, it falls into the general Regulatory Filings category (RNS) as a fallback for miscellaneous regulatory announcements.
2026-04-24 Greek (modern)
Share Issue/Capital Change 2026
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing submitted to the Cyprus Stock Exchange (ΧΑΚ) detailing the distribution of share capital (Συγκεντρωτική Κατάσταση Διασποράς του Μετοχικού Κεφαλαίου) for the company 'ΦΑΡΜΑΚΕΥΤΙΚΟ ΚΕΝΤΡΟ Α.Ε.' as of 31/12/2025. It lists major shareholders, board members' holdings, and share distribution statistics. This type of disclosure is a standard regulatory requirement for listed companies to report their shareholding structure to the exchange. Since it does not fit into specific categories like 'Major Shareholding Notification' (which usually refers to a single entity crossing a threshold) or 'Director's Dealing' (which refers to specific trades), it is classified as a general regulatory filing.
2026-02-02 Greek (modern)

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.